{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:09Z","timestamp":1740108249233,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004820","name":"Mochida Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00198-019-05038-y","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T19:03:25Z","timestamp":1561575805000},"page":"2027-2037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis"],"prefix":"10.1007","volume":"30","author":[{"given":"H.","family":"Hagino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tomomitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"5038_CR1","unstructured":"European Medicines Agency (2018) Forsteo: EPAR - product information (SmPC). \nhttps:\/\/www.ema.europa.eu\/documents\/product-information\/forsteo-epar-product-information_en.pdf\n\n. Accessed 27 December 2018"},{"key":"5038_CR2","unstructured":"Eli Lilly and Company (2013) FORTEO (teriparatide [rDNA origin] injection): Label. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021318s036lbl.pdf\n\n. Accessed 27 December 2018"},{"issue":"18","key":"5038_CR3","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2165\/0003495-200868180-00012","volume":"68","author":"SK Blick","year":"2008","unstructured":"Blick SK, Dhillon S, Keam SJ (2008) Teriparatide: a review of its use in osteoporosis. Drugs 68(18):2709\u20132737","journal-title":"Drugs"},{"issue":"50","key":"5038_CR4","doi-asserted-by":"publisher","first-page":"48868","DOI":"10.1074\/jbc.M208494200","volume":"277","author":"Q Fu","year":"2002","unstructured":"Fu Q, Jilka RL, Manolagas SC, O'Brien CA (2002) Parathyroid hormone stimulates receptor activator of NF\u03baB ligand and inhibits osteoprotegerin expression via protein kinase a activation of cAMP-response element-binding protein. J Biol Chem 277(50):48868\u201348875","journal-title":"J Biol Chem"},{"issue":"11","key":"5038_CR5","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","volume":"138","author":"H Dobnig","year":"1997","unstructured":"Dobnig H, Turner RT (1997) The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138(11):4607\u20134612","journal-title":"Endocrinology"},{"issue":"19","key":"5038_CR6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"3","key":"5038_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","volume":"47","author":"A Miyauchi","year":"2010","unstructured":"Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47(3):493\u2013502","journal-title":"Bone"},{"issue":"15","key":"5038_CR8","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","volume":"165","author":"MR McClung","year":"2005","unstructured":"McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165(15):1762\u20131768","journal-title":"Arch Intern Med"},{"issue":"1","key":"5038_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18(1):9\u201317","journal-title":"J Bone Miner Res"},{"key":"5038_CR10","unstructured":"European Medicines Agency and the European Commission (2017) Biosimilars in the EU information guide for healthcare professionals. \nhttps:\/\/www.ema.europa.eu\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf\n\n. Accessed 27 December 2018"},{"key":"5038_CR11","unstructured":"Medicines for Europe (2016) Biosimilar medicines handbook. 3rd edn. \nhttps:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/04\/Medicines-for- Europe_BIOSIMILARS_INT_web.pdf#search=%27Biosimilar+medicines+handbook%27\n\n. Accessed 22 Nov 2018"},{"key":"5038_CR12","unstructured":"European Medicines Agency (2014) Guideline on similar biological medicinal products. CHMP\/437\/04 Rev 1. \nhttps:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf\n\n. Accessed 27 December 2018"},{"key":"5038_CR13","unstructured":"US Food and Drug Administration (2015) scientific considerations in demonstrating biosimilarity to a reference product. \nhttps:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf\n\n. Accessed 27 December 2018"},{"key":"5038_CR14","unstructured":"Ministry of Health, Labour and Welfare, Japan (2009) Guideline for the quality, safety, and efficacy Assurance of Follow-on Biologics. PFSB\/ELD Notification No. 0304007. \nhttp:\/\/www.pmda.go.jp\/files\/000153851.pdf\n\n. Accessed 27 December 2018"},{"key":"5038_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00198-018-4741-0","volume":"30","author":"I Tak\u00e1cs","year":"2018","unstructured":"Tak\u00e1cs I, J\u00f3kai E, Kov\u00e1ts DE, Aradi I (2018) The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic\/pharmacodynamic study. Osteoporos Int 30:675\u2013683. \nhttps:\/\/doi.org\/10.1007\/s00198-018-4741-0","journal-title":"Osteoporos Int"},{"key":"5038_CR16","unstructured":"European Medicines Agency (2016) Terrosa: EPAR. EMA\/833583\/2016; EMEA\/H\/C\/003916. \nhttps:\/\/www.ema.europa.eu\/documents\/overview\/terrosa-epar-summary-public_en.pdf\n\n. Accessed 27 December 2018"},{"issue":"6","key":"5038_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19(6):331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"5038_CR18","volume-title":"Japanese 2015 guidelines for prevention and treatment of osteoporosis","author":"H Orimo","year":"2015","unstructured":"Orimo H (2015) Japanese 2015 guidelines for prevention and treatment of osteoporosis. Life Science Publishing, Tokyo"},{"key":"5038_CR19","unstructured":"ClinicalTrials.gov\n\n (2018) A comparison of PF708 and Forteo in osteoporosis patients. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03002428\n\n. Accessed 27 December 2018"},{"issue":"3","key":"5038_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00198-011-1843-3","volume":"23","author":"S Yu","year":"2012","unstructured":"Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES (2012) The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 23(3):1103\u20131113","journal-title":"Osteoporos Int"},{"issue":"2","key":"5038_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1185\/03007995.2013.851659","volume":"30","author":"X Nogues","year":"2014","unstructured":"Nogues X, Luz Rentero M, Rodriguez AL (2014) Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide. Curr Med Res Opin 30(2):287\u2013296","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"5038_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00198-008-0698-8","volume":"20","author":"K Briot","year":"2009","unstructured":"Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C (2009) Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 20(4):625\u2013630","journal-title":"Osteoporos Int"},{"issue":"4","key":"5038_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00223-012-9574-9","volume":"90","author":"C Tamone","year":"2012","unstructured":"Tamone C, Fonte G, Panico A, Molinatti PA, D'Amelio P, Isaia GC (2012) Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment. Calcif Tissue Int 90(4):272\u2013278","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"5038_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11657-018-0487-8","volume":"13","author":"M Sato","year":"2018","unstructured":"Sato M, Tsujimoto M, Kajimoto K, Uetake H, Shimoda H, Fujiwara S (2018) Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan fracture observational study (JFOS). Arch Osteoporos 13(1):74. \nhttps:\/\/doi.org\/10.1007\/s11657-018-0487-8","journal-title":"Arch Osteoporos"},{"issue":"3","key":"5038_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00774-011-0314-4","volume":"30","author":"M Tsujimoto","year":"2012","unstructured":"Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H (2012) Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy. J Bone Miner Metab 30(3):326\u2013337","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"5038_CR26","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1359\/jbmr.060802","volume":"21","author":"P Chen","year":"2006","unstructured":"Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006) Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21(11):1785\u20131790","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05038-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T23:20:34Z","timestamp":1593040834000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05038-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05038-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"15 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HH has received consulting fees for this study from Mochida Pharmaceutical and lecture fees or grants outside the submitted work from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. RN, YY, MW, and MT are employees of Mochida Pharmaceutical. All authors declared no other relationships\/conditions\/circumstances that present a potential conflict of interest, in accordance with the \u201cTransparency guideline for the Relation between Corporate Activities and Medical Institutions\u201d prepared by the Japan Pharmaceutical Manufacturers Association, corresponding in Japan to the Physicians Payment Sunshine Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}